(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

EMALEX BIOSCIENCES

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

EMALEX BIOSCIENCES

ST13

US500000098417013

Class

42, 44

Filing

98417013

Registration

8024845

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

30

Latest update

11/12/2025

Trademark type

Combined

Nice classes

42, 44

Filing date

02/22/2024

Registration date

11/11/2025

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

11/11/2025

Last transaction

11/12/2025

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

03/01/2019

First use in commerce

03/01/2019

Drawing code

3

Owner type

03

Owner location

Chicago, IL

Examiner

FAIRBANKS,RONALD L

Law office

N10

Current location

PUBLICATION AND ISSUE SECTION

Mark description

The mark consists of the words "EMALEX BIOSCIENCES" with an arrow shaped gap between the top and bottom of the "X".

Holders and representatives

Holders

Emalex Biosciences, Inc.

Representatives

Kristen Ruisi Venable LLP

Technical classification

Nice Classes

Class 42Class 44

Vienna Codes

No Vienna codes available.

Goods and services

Class 42

Research and development of medications and treatment for central nervous system disorders

Class 44

Providing healthcare and medical information; healthcare servicesnamely providing information in the field of healthwellnessTourette Syndrome and other central nervous system disorders; providing website featuring information in the field of central nervous system disorders treatments; providing informationnewscommentary in the field of central nervous system disorders

Publications

History of USPTO decisions and trademark events.

30 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

11/11/2025

R.PR

REGISTERED-PRINCIPAL REGISTER

11/11/2025

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

10/17/2025

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

10/17/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

10/14/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

10/14/2025

ALIE

ASSIGNED TO LIE

10/14/2025

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

10/03/2025

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

09/30/2025

GNRT

NON-FINAL ACTION E-MAILED

09/30/2025

CNRT

SU - NON-FINAL ACTION - WRITTEN

09/30/2025

SUPC

STATEMENT OF USE PROCESSING COMPLETE

08/13/2025

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

08/13/2025

IUAF

USE AMENDMENT FILED

11/26/2024

EISU

TEAS STATEMENT OF USE RECEIVED

11/26/2024

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

11/26/2024

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

10/15/2024

PUBO

PUBLISHED FOR OPPOSITION

10/15/2024

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

09/25/2024

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

09/10/2024

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

09/10/2024

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

09/10/2024

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

09/10/2024

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

08/28/2024

GNRT

NON-FINAL ACTION E-MAILED

08/28/2024

CNRT

NON-FINAL ACTION WRITTEN

08/28/2024

DOCK

ASSIGNED TO EXAMINER

08/27/2024

MDSC

NOTICE OF DESIGN SEARCH CODE E-MAILED

07/13/2024

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

07/13/2024

NWAP

NEW APPLICATION ENTERED

02/22/2024

Continuous trademark protection

Get notified about every new filing that threatens EMALEX BIOSCIENCES or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.